Trials / Completed
CompletedNCT05565729
A Phase I Study of LY3471851 in Healthy Participants
A Phase 1, Randomized, Placebo-controlled, Participant- and Investigator-blind, Single-dose Study of the Pharmacokinetics of LY3471851 Following Subcutaneous Dosing of LY3471851 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (actual)
- Sponsor
- Nektar Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare two different formulations (test \& reference) of LY3471851 in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving the study drug that is LY3471851.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3471851 | Administered SC. |
| DRUG | Placebo | Administered SC. |
| DRUG | Levocetirizine | Administered orally. |
Timeline
- Start date
- 2022-10-05
- Primary completion
- 2023-02-23
- Completion
- 2023-02-23
- First posted
- 2022-10-04
- Last updated
- 2023-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05565729. Inclusion in this directory is not an endorsement.